Lipid Nanoparticle (LNP) News Brief Summary (May 13 – May 26, 2025)
News Summary
Innorna: Presented new data on mRNA-LNP therapies for PFIC2 and Wilson’s Disease at ASGCT 2025.
University of Nottingham, MIT, Sail Biomedicines: Developed cryogenic mass spectrometry to analyze LNP surface structures.
Sail Biomedicines: Announced preclinical data on in vivo eRNA CAR-T candidate SAIL-0804 for autoimmune diseases.
Arcturus Therapeutics: SWOT analysis highlighted LNP platform advancements and pipeline progress.
ResearchAndMarkets.com: Reported mRNA platform market growth driven by LNP delivery innovations.
Detailed News Summaries
Innorna: Advances in mRNA-LNP Therapies at ASGCT 2025
Release Date: May 13, 2025
Related Institutions: Innorna (Boston, Hong Kong, Shenzhen, China).
Innorna presented two posters at the ASGCT Annual Meeting showcasing mRNA-LNP formulations targeting Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC2) and Wilson’s Disease. Their LNPs demonstrated high liver-targeting efficiency and safety in preclinical models, supporting clinical translation for rare liver diseases.
University of Nottingham, MIT, Sail Biomedicines: Cryo-OrbiSIMS for LNP Analysis
Release Date: May 22, 2025
Authors: Professor Morgan Alexander (Nottingham), Dr. Robert Langer (MIT), Kerry Benenato (Sail Biomedicines).
Related Institutions: University of Nottingham (Nottingham, UK); MIT (Cambridge, MA, USA); Sail Biomedicines (Cambridge, MA, USA); National Physical Laboratory (Teddington, UK).
A collaborative study published in Nature introduced Cryogenic Orbitrap Secondary Ion Mass Spectrometry (Cryo-OrbiSIMS) to map molecular layers in hydrated LNPs. This method revealed PEG-lipid orientation and RNA distribution, enabling precise engineering of LNPs for improved drug delivery.
Sail Biomedicines: Preclinical Data on SAIL-0804 for Autoimmune Diseases
Release Date: May 13, 2025
Related Institutions: Sail Biomedicines (Cambridge, MA, USA).
Sail Biomedicines presented data on SAIL-0804, an in vivo CAR-T therapy delivered via targeted LNPs. The candidate induced rapid B-cell depletion in preclinical models, supporting its advancement into IND-enabling studies for autoimmune diseases.
Arcturus Therapeutics: SWOT Analysis Highlights LNP Platform
Release Date: May 24, 2025
Link: Arcturus SWOT Analysis
Related Institutions: Arcturus Therapeutics (San Diego, CA, USA).
A financial analysis highlighted Arcturus’ LUNAR® LNP platform, which underpins its self-amplifying mRNA pipeline. Key programs include ARCT-032 (cystic fibrosis) and ARCT-2304 (H5N1 vaccine), with Phase 2 data expected in 2025.
mRNA Platform Market Report: LNP Delivery Innovations
Release Date: May 23, 2025
Link: mRNA Market Report
Related Institutions: ResearchAndMarkets.com (Dublin, Ireland).
The report projected the mRNA market to reach $8.93B by 2030, driven by LNP advancements improving stability and cellular uptake. Collaborations like BioNTech-CEPI for mpox vaccines were cited as growth catalysts.
Thanks for assembling this LNP news brief! Keeping up with the rapid advances in lipid nanoparticle delivery and nanomedicine can be intense. Whenever my brain feels completely fried after diving into complex biotech reports and research summaries, I usually take a quick break on minigame. It’s completely free with instant-play browser games and zero downloads required—super nice for a fast mental reset!
The ragdoll movement makes ragdoll archers pretty entertaining. Sometimes a shot works in a way I didn't expect, which keeps the gameplay from feeling too predictable.